{"DataElement":{"publicId":"6242625","version":"1","preferredName":"Cutaneous Melanoma AJCC Edition 8 Pathologic Group Stage","preferredDefinition":"Pathologic stage group based on the combination of T, N, and M categories and relevant prognostic factors for skin melanoma, using AJCC Ed. 8 criteria.","longName":"CMEL_AJC8_PTH_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6072294","version":"1","preferredName":"Cutaneous Melanoma Pathologic Stage Grouping","preferredDefinition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma._Caused by or altered by or manifesting disease or pathology._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"2431290v1.0:2230144v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2431290","version":"1","preferredName":"Cutaneous Melanoma","preferredDefinition":"A malignant neoplasm derived from cells that are capable of forming melanin.","longName":"C3510","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Melanoma","conceptCode":"C3510","definition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF3BE-971D-3B79-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230144","version":"1","preferredName":"Pathologic Stage Grouping","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25610:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CCE-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"65422D89-F474-7A39-E053-F662850A3C9E","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-15","modifiedBy":"TAYLORT","dateModified":"2018-06-11","changeDescription":"2/15/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6229599","version":"1","preferredName":"Cutaneous Melanoma American Joint Committee on Cancer Edition 8 Pathologic Group Stage","preferredDefinition":"A term that refers to the pathologic staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6229599v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Pathologic Stage IV Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229623","version":"1","preferredName":"Pathologic Stage IV Cutaneous Melanoma AJCC v8","longName":"6229623","preferredDefinition":"Stage IV includes: Any T, Tis, Any N, M1. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. M1: Evidence of distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IV Cutaneous Melanoma AJCC v8","conceptCode":"C137677","definition":"Stage IV includes: Any T, Tis, Any N, M1. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. M1: Evidence of distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A7611-B26F-1A09-E053-F662850A7C56","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A7611-B288-1A09-E053-F662850A7C56","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIID","valueDescription":"Pathologic Stage IIID Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229625","version":"1","preferredName":"Pathologic Stage IIID Cutaneous Melanoma AJCC v8","longName":"6229625","preferredDefinition":"Stage IIID includes: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIID Cutaneous Melanoma AJCC v8","conceptCode":"C137675","definition":"Stage IIID includes: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A7611-B295-1A09-E053-F662850A7C56","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A7611-B2AE-1A09-E053-F662850A7C56","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229627","version":"1","preferredName":"Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","longName":"6229627","preferredDefinition":"Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration.  T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","conceptCode":"C137672","definition":"Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration.  T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A7611-B2BB-1A09-E053-F662850A7C56","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A7611-B2D4-1A09-E053-F662850A7C56","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229629","version":"1","preferredName":"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","longName":"6229629","preferredDefinition":"Stage IIIA includes: T1a/b-T2a, N1a or N2a, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","conceptCode":"C137671","definition":"Stage IIIA includes: T1a/b-T2a, N1a or N2a, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A7611-B2E1-1A09-E053-F662850A7C56","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A7611-B2FA-1A09-E053-F662850A7C56","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6242623","version":"1","preferredName":"Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","longName":"6242623","preferredDefinition":"Refer to NCIt C137673","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B27F5CD-DBA1-27DE-E053-F662850A78A2","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-01","modifiedBy":"TAYLORT","dateModified":"2018-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B177254-9D9C-7FC5-E053-F662850A7473","beginDate":"2018-05-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","deletedIndicator":"No"},{"value":"IIC","valueDescription":"Pathologic Stage IIC Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229601","version":"1","preferredName":"Pathologic Stage IIC Cutaneous Melanoma AJCC v8","longName":"6229601","preferredDefinition":"Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIC Cutaneous Melanoma AJCC v8","conceptCode":"C137669","definition":"Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-9179-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-9192-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Pathologic Stage IIB Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229603","version":"1","preferredName":"Pathologic Stage IIB Cutaneous Melanoma AJCC v8","longName":"6229603","preferredDefinition":"Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIB Cutaneous Melanoma AJCC v8","conceptCode":"C137668","definition":"Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-919F-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-91B8-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Pathologic Stage IIA Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229605","version":"1","preferredName":"Pathologic Stage IIA Cutaneous Melanoma AJCC v8","longName":"6229605","preferredDefinition":"Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IIA Cutaneous Melanoma AJCC v8","conceptCode":"C137667","definition":"Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-91C5-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-91DE-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IB","valueDescription":"Pathologic Stage IB Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229609","version":"1","preferredName":"Pathologic Stage IB Cutaneous Melanoma AJCC v8","longName":"6229609","preferredDefinition":"Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IB Cutaneous Melanoma AJCC v8","conceptCode":"C137665","definition":"Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-9211-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-922A-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"IA","valueDescription":"Pathologic Stage IA Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229611","version":"1","preferredName":"Pathologic Stage IA Cutaneous Melanoma AJCC v8","longName":"6229611","preferredDefinition":"Stage IA includes: (T1a, N0, M0); (T1b, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage IA Cutaneous Melanoma AJCC v8","conceptCode":"C137664","definition":"Stage IA includes: (T1a, N0, M0); (T1b, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-9237-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-9250-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"},{"value":"0","valueDescription":"Pathologic Stage 0 Cutaneous Melanoma AJCC v8","ValueMeaning":{"publicId":"6229615","version":"1","preferredName":"Pathologic Stage 0 Cutaneous Melanoma AJCC v8","longName":"6229615","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Stage 0 Cutaneous Melanoma AJCC v8","conceptCode":"C137662","definition":"Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-9283-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6A8A525F-929C-1A39-E053-F662850A5362","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6229598","version":"1","preferredName":"Cutaneous Melanoma by AJCC v8 Pathologic Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the pathologic staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C137657:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Melanoma by AJCC v8 Pathologic Stage","conceptCode":"C137657","definition":"A term that refers to the pathologic staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A8A525F-914C-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"ONEDATA","dateModified":"2018-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6A8A525F-915D-1A39-E053-F662850A5362","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-23","modifiedBy":"TAYLORT","dateModified":"2018-06-11","changeDescription":"6/11/18 released by tt. 4/23/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000090","version":"1","longName":"Cutaneous Melanoma","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634324","version":"1","longName":"CM Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"OCCPR","type":"USED_BY","context":"OCCPR"}],"ReferenceDocuments":[{"name":"Pathologic disease stage","type":"Preferred Question Text","description":"Pathologic disease stage","url":null,"context":"NCI Standards"},{"name":"CPTAC-BSLN-1","type":"Alternate Question Text","description":"Tumor Stage (Pathologic)","url":null,"context":"OCCPR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6B26B125-E00A-2DC3-E053-F662850AE36E","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-01","modifiedBy":"KNABLEJ","dateModified":"2021-07-26","changeDescription":"6/11/18 released by tt. 5/1/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}